Prostate Oncology Specialists Among First in the Nation to Treat Advanced Prostate Cancer Patients With PROVENGE
MARINA DEL REY, Calif., Oct. 27 /PRNewswire/ -- Prostate Oncology Specialists, Inc. of Marina del Rey is among the first sites in the nation to treat advanced prostate cancer patients with PROVENGE® (sipuleucel-T), the first in a new therapeutic class known as autologous cellular immunotherapies. PROVENGE was approved by the U.S. Food and Drug Administration (FDA) for the treatment of men with asymptomatic or minimally symptomatic metastatic castrate resistant (hormone refractory) prostate cancer and is made by Dendreon Corporation.
"PROVENGE is a scientific breakthrough that paves the way for similar personalized treatments in other cancer types," said Dr. Mark Scholz, Medical Director of Prostate Oncology Specialists and co-founder of the Prostate Cancer Research Institute. "I'm pleased to have a new option to present to my patients and to be a part of the first physician-based facility in the area treating patients with this important new FDA approved therapy."
Prostate Oncology Specialists have treated over 30 patients with PROVENGE to date, and anticipates providing the therapy to many more men with metastatic castrate resistant prostate cancer as supply of the drug increases over the next six months.
"I was excited about using PROVENGE because it allowed me to use my own cells to help fight cancer," said PROVENGE patient Frank La Barba of Long Beach, CA. "My side-effects were mild and following my treatment, I was able to get back to doing the activities I did before receiving therapy, such as traveling and photography."
PROVENGE is an autologous (made from a patient's own immune cells) cellular immunotherapy designed to stimulate a patient's